Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR
Public ClinicalTrials.gov record NCT05635045. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Follow-Up Study to Monitor Therapeutic Response in Transthyretin Cardiac Amyloidosis Using Amyloid Reactive Peptide 124I-evuzamitide (AT01) PET/CT
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a single center, prospective cohort study that is evaluating the ability of 124I-evuzamitide PET scanning to detect potential therapeutic changes in subjects under treatment for ATTR after one year had elapsed since their original 124I-evuzamitide PET scan. Ten previously scanned subjects re-consented to undergo another 124I-evuzamitide PET scan. Demographic, clinical and phenotypic data were collected to characterize potential changes since their previous scans.
Study identification
- NCT ID
- NCT05635045
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 105 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 7, 2022
- Primary completion
- May 6, 2024
- Completion
- Jun 11, 2024
- Last update posted
- Jul 17, 2025
2022 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Columbia University Irving Medical Center | New York | New York | 10032 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Transthyretin Amyloidosis trials
Other public records listing Transthyretin Amyloidosis. Sorted by last update posted; newest first. Not a recommendation.
- NCT07695701: Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis Recruiting
- NCT06563895: Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant Recruiting
- NCT06465810: Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis Recruiting
- NCT05758493: Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis Recruiting
- NCT05577819: Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05635045, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 17, 2025 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05635045 live on ClinicalTrials.gov.